HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Identification of a pyroptosis-associated long non-coding RNA signature for predicting the immune status and prognosis in skin cutaneous melanoma.

AbstractOBJECTIVE:
Pyroptosis is correlated with programmed tumor cell death and the tumor microenvironment. However, the prognostic value of pyroptosis-associated long non-coding RNAs (lncRNAs) in skin cutaneous melanoma (SKCM), a malignant tumor with a poor prognosis, has not been established.
PATIENTS AND METHODS:
In this study, expression profiles and clinical data of patients with SKCM were downloaded from The Cancer Genome Atlas (TCGA) database to identify differentially expressed pyroptosis-related lncRNAs related to overall survival. A lncRNA risk signature was constructed by Cox regression analyses and its prognostic value was evaluated. Associations between the lncRNA signature and immune status, immune microenvironment, tumor stemness, immune checkpoints, and m6A-related genes were further evaluated.
RESULTS:
Twenty-two pyroptosis-related lncRNAs were identified and incorporated into a prognostic risk signature. The signature was significantly correlated with overall survival, tumor growth, and metastasis in SKCM. The signature demonstrated better diagnostic accuracy than conventional clinicopathological characteristics. A gene set enrichment analysis indicated that the risk signature was enriched in several immune-related pathways. Furthermore, the risk signature was significantly correlated with the immune microenvironment, immune cell infiltration, and immune subtypes, as well as tumor stem cells and some m6A-related genes. The lncRNA expression levels were also significantly related to responses to several anti-tumor drugs. Finally, a nomogram based on the risk score was established.
CONCLUSIONS:
Overall, a risk signature based on 22 pyroptosis-associated lncRNAs was generated, providing a novel perspective on the determinants of prognosis and survival in SKCM and a basis for the development of individualized treatments.
AuthorsL Wu, G Liu, Y-W He, R Chen, Z-Y Wu
JournalEuropean review for medical and pharmacological sciences (Eur Rev Med Pharmacol Sci) Vol. 25 Issue 18 Pg. 5597-5609 (09 2021) ISSN: 2284-0729 [Electronic] Italy
PMID34604952 (Publication Type: Journal Article)
Chemical References
  • RNA, Long Noncoding
  • Methyltransferases
  • METTL3 protein, human
Topics
  • Female
  • Gene Expression
  • Humans
  • Male
  • Melanoma (genetics, immunology, mortality, pathology)
  • Methyltransferases (genetics)
  • Middle Aged
  • Prognosis
  • Pyroptosis (genetics)
  • RNA, Long Noncoding (genetics, metabolism)
  • Risk Factors
  • Skin Neoplasms (genetics, immunology, mortality, pathology)
  • Survival Rate
  • Tumor Microenvironment (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: